Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.51 |
| ▸ | ACE | P12821 | 9/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.46 |
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30315374 | 0.86 | REN (0.51) | RENACEACE2LTA4HKDM4E | |
| SCHEMBL31072134 | 0.85 | XIAP (0.50) | REN | |
| SCHEMBL29510749 | 0.82 | ACE (0.53) | RENACEACE2LTA4HKDM4E | |
| SCHEMBL9471485 | 0.81 | ACE (0.48) | RENACEACE2LTA4HKDM4E | |
| SCHEMBL9347620 | 0.80 | ACE (0.51) | RENACEACE2LTA4HKDM4E | |
| SCHEMBL9347633 | 0.80 | ACE (0.51) | RENACEACE2LTA4HKDM4E | |
| SCHEMBL30692365 | 0.80 | ACE (0.51) | RENACEACE2LTA4HKDM4E | |
| SCHEMBL28313314 | 0.80 | ACE (0.48) | RENACEACE2LTA4HKDM4E | |
| SCHEMBL28313317 | 0.80 | ACE (0.48) | RENACEACE2LTA4HKDM4E | |
| SCHEMBL29839268 | 0.79 | REN (0.47) | RENACEACE2LTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| CN-118556062-A | Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders | 文赛克斯制药有限责任公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-4412655-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | PTK2, PCNA, CDK4 | REN 2571/4885ACE 2607/4885ACE2 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.